Every compound. Clear answers. No fluff.
For Research Purposes Only
Peptides for hair regrowth, skin elasticity, complexion, and melanin regulation. Most of these work synergistically — see the stacking section below each compound.
AHK-Cu is a copper tripeptide complex that stimulates hair follicle growth by activating stem cell markers and promoting dermal papilla function. It shares copper's wound-healing and anti-inflammatory benefits while specifically targeting the scalp microenvironment. Distinct from GHK-Cu in its selectivity for follicular tissue.
Topical: 0.1–0.5% solution applied to scalp 1–2x daily. Injectable (subcutaneous): 200–500 mcg per injection site, 2–3x per week. Results typically visible at 8–12 weeks of consistent use.
Cycle: 3–6 months continuous use for hair regrowth. 6 weeks on, 2 weeks off for subcutaneous protocol. Can be used indefinitely topically. Onset: Hair density changes visible at 8–12 weeks minimum.
Cycle: 3–6 months continuous use for hair regrowth. 6 weeks on, 2 weeks off for subcutaneous protocol. Can be used indefinitely topically. Onset: Hair density changes visible at 8–12 weeks minimum.
Minimal reported side effects. Possible mild scalp irritation at higher concentrations. Avoid high copper intake simultaneously as topical + systemic copper can accumulate. Not studied in pregnancy.
GHK-Cu is one of the most studied copper peptides in existence, with over 50 years of research. It naturally occurs in human plasma and declines sharply with age. It acts as a master regulator of wound healing, skin remodeling, and antioxidant gene expression, activating over 4,000 genes.
Topical: 0.05–0.1% in serum or cream, applied 1–2x daily. Injectable: 500 mcg – 2 mg subcutaneous, 3–5x per week. Can be combined with microneedling for enhanced dermal penetration.
Cycle: Topical: indefinite daily use. SubQ: 4–8 week courses, 2–4 weeks off, repeat. Onset: Skin quality 4–6 weeks; hair improvements 8–12 weeks.
Very well tolerated. Potential temporary skin purging (increased cell turnover) in first 2 weeks. Rare reports of mild redness at injection site. Do not use with strong retinoids on the same skin area simultaneously.
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It activates melanocortin receptors (MC1R–MC4R), producing tanning without UV exposure, while also exerting powerful libido-enhancing effects via MC4R activation in the hypothalamus.
Loading: 100–250 mcg subcutaneous, gradually titrate up to 500–1000 mcg. Inject in evening — nausea is common and passes with sleep. Maintenance: 250–500 mcg 2–3x per week once desired tan achieved. Loading phase: 2–4 weeks.
Loading: 2–4 weeks until target tan. Maintenance: 250–500 mcg 2–3x/week. Breaks: 2–4 weeks off every 2–3 months. Monitor moles regularly.
Common: nausea (dose-dependent), facial flushing, spontaneous erections, yawning, fatigue. Important: Monitor existing moles — MT-2 can darken moles. Get a dermatology check before extended use. Not recommended for fair-skinned individuals with many moles or family history of melanoma.
Melanotan I (MT-1), now known clinically as afamelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike Melanotan II, MT-1 is a linear peptide with significantly higher selectivity for the MC1R receptor — the receptor responsible for melanin synthesis — with minimal activity at MC3R, MC4R (which drive MT-2's libido and appetite effects). This makes MT-1 a "cleaner" tanning peptide with substantially fewer systemic side effects. It is FDA-approved (as Scenesse) for the rare condition erythropoietic protoporphyria (EPP), a painful photosensitivity disorder.
Injectable research use: 0.5–1 mg subcutaneous, once daily or every other day during loading phase. Inject in the evening to minimize any flushing side effects during sleep. Loading phase: 2–4 weeks for initial pigmentation development. Maintenance: 0.5–1 mg 2–3x per week. Less total dose required than MT-2 due to longer receptor binding. Results visible at 2–4 weeks with UV exposure.
Loading: 2–4 weeks. Maintenance: 0.5–1 mg 2–3x/week. Breaks: 2 weeks off every 2–3 months. Monitor moles every 6 months.
Common: Mild flushing, mild nausea (much less than MT-2), yawning, facial flushing — all dose-dependent and transient. Important: Monitor existing moles — like all melanocortin agonists, MT-1 can darken existing nevi. Get a dermatology baseline before extended use. Not recommended for individuals with numerous atypical moles or personal/family history of melanoma.
RU58841 is a potent non-steroidal androgen receptor antagonist developed in the 1970s. Applied topically, it blocks DHT from binding to hair follicle androgen receptors — the primary driver of male and female pattern hair loss — without significant systemic anti-androgenic effects when used correctly.
Topical: 50–75 mg dissolved in a carrier (propylene glycol/ethanol solution), applied to affected scalp once daily. Consistency is essential — missing doses allows DHT to act. Results visible at 3–6 months.
Cycle: Continuous daily use required. AR blockade stops when application stops. Onset: Shedding reduction at 2–3 months; regrowth at 4–6 months.
Low systemic absorption with proper topical use. Some users report temporary shedding in weeks 2–4 (normal cycling). Rare: mild scalp dryness or irritation. Avoid oral use — systemic anti-androgenic effects become significant.
Originally developed as a blood pressure medication, minoxidil's hair growth effects were discovered serendipitously. As a potassium channel opener, it dilates scalp blood vessels and extends the anagen (growth) phase of hair follicles. It is the most widely used and clinically validated hair loss treatment available.
Topical 5%: 1 mL applied 2x daily. Oral: 0.5–5 mg once daily (physician guidance recommended). Topical can be applied under peptide serums for combined delivery. First signs of regrowth at 3–6 months; full effects at 12 months.
Cycle: Continuous long-term use required — loss returns within 3–6 months of stopping. Onset: Normal initial shedding at 4–8 weeks; regrowth at 3–6 months.
Topical: Scalp dryness, irritation, initial shedding. Oral: Fluid retention, heart rate increase, unwanted facial/body hair, headaches. Not recommended in pregnancy. Monitor blood pressure with oral use.
Klow is a targeted scalp health formulation combining growth-stimulating peptides and anti-inflammatory agents. It works by improving scalp microbiome health, reducing chronic inflammation (a common but overlooked hair loss driver), and delivering follicle-stimulating nutrients directly to the dermal papilla.
Apply to scalp per product instructions, typically 1–2x daily on clean dry hair. Best paired with a complete hair loss protocol rather than used alone.
Cycle: 6–8 weeks on, 2–4 weeks off. Onset: Inflammation reduction 2 weeks; hair quality 8+ weeks.
Very well tolerated as a multi-peptide combination. Rare: mild injection site reaction (BPC-157/TB-500 components), transient scalp irritation. No hormonal effects. Check individual compound profiles for specific considerations.
FollicRX is a peptide blend formulated specifically for hair follicle rescue and regrowth. It combines multiple signaling peptides to address the root causes of hair thinning — poor follicle nourishment, inflammatory cytokines, and impaired stem cell activation — in a single topical application.
The Glow stack is a pre-formulated combination of three of the most powerful tissue-repair and skin-regenerating peptides. BPC-157 drives vascular growth and inflammation control, TB-500 promotes cell migration and elasticity, and GHK-Cu stimulates collagen synthesis and antioxidant gene expression.
Per component: BPC-157 250–500 mcg/day, TB-500 2–5 mg/week, GHK-Cu 1–2 mg/week subcutaneous or topical. Run for 8–12 weeks, 4-week break, repeat.
Cycle: 4–8 weeks on, 2–4 weeks off. Topical: daily continuous use is sustainable long-term.
Very well tolerated as a combination. Rare: mild injection site reaction, temporary skin purging (GHK-Cu effect — normal). Individual component profiles (BPC-157, TB-500, GHK-Cu) are all well studied with excellent safety records.
PP405 is a first-in-class investigational topical compound developed by Pelage Pharmaceuticals at UCLA. Rather than blocking DHT or dilating blood vessels like existing treatments, PP405 works by inhibiting the mitochondrial pyruvate carrier (MPC1 and MPC2) in hair follicle stem cells. This metabolic shift from oxidative phosphorylation to glycolysis mimics the active anagen (growth) phase of the hair cycle — essentially reprogramming dormant follicles to wake up and grow. As of Phase 2a clinical trials (2025–2026), PP405 has shown measurable increases in hair density with no systemic absorption detected in blood.
PP405 temporarily blocks pyruvate entry into mitochondria. This causes pyruvate to accumulate in the cytoplasm, stimulating lactate dehydrogenase (LDH) activity and increasing intracellular lactate and glycolysis. Research shows that high lactate availability in hair follicle stem cells is a key signal for entering the growth phase. Low lactate = dormancy (telogen). High lactate = active growth (anagen). PP405 shifts follicles into the high-lactate, high-energy state required for terminal hair production — without hormonal interference.
Phase 2a clinical trials ongoing (2025–2026) in the US by Pelage Pharmaceuticals. Phase 2a open-label extension data expected in 2026. Estimated earliest approval: 2027–2028 in the US, 2029–2030 elsewhere. Not currently available for purchase. The compound's chemical structure has not been publicly disclosed. PP405 is NOT JXL069 or JXL082 — Pelage Pharmaceuticals has explicitly stated this. Sourcing or purchasing compounds claiming to be PP405 carries significant risk of receiving a counterfeit or misidentified substance.
Phase 1 protocol: 0.05% topical gel applied once nightly to scalp. Engineered for 1,000x better skin penetration than blood penetration — designed to stay local. Observable cellular activation (Ki67 marker increase) detected within 7 days of application in Phase 1. Not available outside of clinical trials at this time.
Status: Phase 2a clinical trials only. Not available outside trials. Estimated approval 2027–2028. No established consumer protocol.
No major side effects reported in Phase 1 and Phase 2a trials. No systemic absorption detected. Local scalp reactions not noted as significant. Long-term safety data is not yet available. Being designed as unstable in blood specifically to minimize systemic risk.
No major side effects reported in Phase 1 and Phase 2a trials. No systemic absorption detected. Minimal scalp reactions. Long-term safety data not yet available. Designed to be unstable in blood to minimize systemic risk. Not available outside clinical trials at this time.
CB-03-01 — known as clascoterone and branded as Breezula (hair loss) and Winlevi (acne) — is a topical synthetic androgen receptor antagonist developed by Cassiopea/Cosmo Pharmaceuticals. Already FDA-approved at 1% for acne (Winlevi, 2020), it is under Phase III trials at 5–7.5% for androgenetic alopecia. Like RU58841, it blocks DHT from binding to androgen receptors in hair follicles — but as a steroidal antiandrogen with a distinct chemical structure and a more advanced clinical evidence base. It shows no detectable systemic absorption and no sexual side effects in trials — the critical advantage over oral finasteride.
Phase II completed 2021: Positive results at 7.5% (men) and 5% (women under 30). Phase III ongoing: 726 participants, 12-month duration, 5% CB-03-01 solution twice daily. Completion expected 2025–2026. FDA approval timeline: Earliest 2026–2027 for hair loss indication. Currently available as a research chemical and compoundable from Winlevi off-label.
Topical solution: 5–7.5% applied twice daily to affected scalp areas. Phase II protocol used morning and evening application. Can be compounded from raw powder in a propylene glycol/ethanol carrier. Continuous daily use is required — AR antagonism ceases when application stops. Results at 6–12 months.
Cycle: Continuous daily use required. Onset: Hair density at 6–12 months; acne improvement at 8–12 weeks.
No systemic anti-androgenic side effects in trials. Local: Mild scalp irritation, dryness, and occasional redness. Manageable with hydrating scalp treatment applied separately. Theoretical risk of skin atrophy with very extended use (steroidal compound) — not observed in trial durations. Use at prescribed concentrations only.
Tissue repair, cellular energy restoration, immune modulation, and sleep optimization. These compounds support the body's natural healing capacity at the molecular level.
BPC-157 is a 15-amino acid peptide fragment derived from a protein found naturally in gastric juice. It is one of the most versatile and well-researched healing peptides available, with documented effects on tendons, ligaments, muscles, the GI tract, nerves, and the vascular system. Acts primarily by upregulating VEGF (vascular endothelial growth factor) and modulating the nitric oxide system.
Systemic/Injury: 250–500 mcg subcutaneous or intramuscular, 1–2x daily near the injury site. Gut health: 250 mcg oral on empty stomach works — oral BPC-157 is active in the GI tract. Cycle: 4–8 weeks on, 2–4 weeks off.
Cycle: 4–8 weeks on, 2–4 weeks off for acute injury. Chronic conditions: 12-week cycles, 4-week breaks. Onset: Gut: 1–2 weeks; joint/tendon: 2–4 weeks.
Extremely well tolerated. Rare: mild dizziness or head rush (due to nitric oxide effects), temporary nausea at high doses. No significant hormonal interference. One of the safest peptides for long-term use.
TB-500 is a synthetic fragment of Thymosin Beta-4, a ubiquitous protein present in virtually every cell. It promotes actin polymerization, enabling cell migration — the fundamental first step in tissue repair. TB-500 has an exceptional distribution profile: injected subcutaneously, it travels systemically to areas of damage.
Loading phase: 2–2.5 mg subcutaneous twice weekly for 4–6 weeks. Maintenance: 2–2.5 mg once weekly or bi-weekly. Can be injected anywhere — it distributes systemically. Reconstitute with 1–2 mL bacteriostatic water.
Loading phase: 4–6 weeks at 2x/week. Maintenance: Weekly or bi-weekly. Breaks: 4–6 weeks off after every 8–12 week cycle.
Very well tolerated. Mild: fatigue and lethargy in first 1–2 days after injection (immune activation). Rare: head rush, temporary dizziness. No steroid-like side effects. Safe for extended use.
NAD+ is a coenzyme found in every cell, essential for energy metabolism, DNA repair, and sirtuins (longevity proteins). Levels decline by 50% between ages 40–60. Supplementation restores cellular energy production, activates SIRT1/SIRT3 pathways, and repairs DNA damage — making it one of the most impactful longevity interventions available.
IV (most effective): 250–750 mg administered slowly over 2–4 hours. Common to feel flush and chest tightness — slow the drip. Subcutaneous: 50–100 mg daily or alternate days. Oral NMN/NR precursors: 500 mg–1 g daily (less bioavailable but convenient).
Cycle: SubQ/oral: sustainable indefinitely. IV: 4–8 loading sessions then monthly. Oral NMN 500 mg–1 g daily: continuous. No tolerance risk.
IV NAD+ commonly causes flushing, chest tightness, and cramping — these are rate-dependent and resolve when slowed. Subcutaneous: mild injection site discomfort. Oral: GI upset at high doses. Generally very safe.
SS-31 is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it protects cardiolipin — a critical phospholipid required for proper electron transport chain function. By stabilizing cardiolipin, SS-31 dramatically improves mitochondrial efficiency and reduces ROS (reactive oxygen species) production. FDA approved in 2025 for Barth syndrome.
Subcutaneous: 2–10 mg daily. Research protocols have used 0.05 mg/kg/hr IV in acute settings. For general wellness/longevity: 2–4 mg/day subcutaneous, 5 days on / 2 days off.
Cycle: 5 days on / 2 days off weekly. 8–12 week courses, 4 weeks off. Long-term use supported by clinical trial data.
Very well tolerated. Rare: mild injection site reaction. No significant systemic side effects in clinical trials. Among the best-tolerated longevity compounds available. FDA-approved for Barth syndrome provides strong safety precedent.
KPV is a tripeptide derived from the C-terminal of alpha-MSH. It acts on melanocortin receptors in immune cells to suppress inflammatory cytokine production (TNF-α, IL-1β, IL-6) without immune suppression. Particularly effective in the GI tract, where it can be taken orally and acts directly on intestinal epithelium.
Oral: 250–500 mcg on empty stomach, 1–2x daily. Subcutaneous: 500 mcg–1 mg daily for systemic effects. Cycle 8 weeks on, 4 weeks off.
Cycle: 8 weeks on, 4 weeks off. Anti-inflammatory effects build over 2–4 weeks. Repeat cycles as clinically indicated.
Very well tolerated. Rare: mild GI discomfort at high oral doses. No immunosuppressive effects. Safe for extended use cycles.
DSIP is a naturally occurring neuropeptide that promotes slow-wave (delta) sleep — the most restorative sleep stage for physical recovery and GH secretion. It modulates the stress response, reduces corticotropin release, and has shown promise in chronic pain and insomnia treatment.
Nasal spray: Available as intranasal form — preferred for convenience. Subcutaneous: 100–200 mcg 30–60 minutes before bed. Start low. Can be used nightly or as needed for sleep issues. Cycle: 2–4 weeks on, break as needed.
Cycle: 2–4 weeks on, 2 weeks off. 3–5x/week rather than daily to prevent receptor adaptation. Onset: Sleep improvement in 3–7 days.
Very well tolerated. Rare: mild drowsiness, transient headache. No next-day sedation at standard doses. No withdrawal on discontinuation. Do not use before driving.
Thymosin Alpha-1 is a 28-amino acid peptide derived from the thymus gland. It is FDA-approved in 37 countries for hepatitis B and C. It functions as a master immune modulator — upregulating T-cell function, NK cell activity, and dendritic cell maturation while reducing chronic inflammatory tone. Critical for immune surveillance against cancer and infections.
Standard: 1.6 mg subcutaneous, twice weekly. Immune boost protocol: Daily for 2–4 weeks. Maintenance: Once weekly indefinitely. Well tolerated long-term.
Cycle: 4–12 week cycles, 4–8 weeks off. Ongoing twice weekly is well tolerated for maintenance. Onset: Immune markers improve at 4–6 weeks.
Very well tolerated. Rare: mild injection site redness, transient fatigue (immune activation sign — normal). No immunosuppressive effects. Safe for long-term use.
Glutathione is the body's master antioxidant tripeptide (glutamate-cysteine-glycine). It is present in every cell, essential for detoxification, immune function, and redox balance. Levels decline with age, stress, alcohol, and chronic disease. IV/subcutaneous glutathione bypasses the poor oral bioavailability of standard supplements.
IV push: 600–1200 mg in normal saline, slow push. Nebulized: 200–400 mg for lung delivery. Subcutaneous: 200–400 mg daily. Liposomal oral: 500 mg–1 g daily (far better than standard oral).
Cycle: SubQ/oral: 8–12 weeks on, 2–4 weeks off or continuous. IV: weekly loading then monthly maintenance.
IV: flushing, chest tightness, cramping — rate-dependent, slow the drip to manage. SubQ: mild injection site discomfort. Oral: GI upset at high doses. Very safe overall across all forms.
Growth hormone secretagogues, IGF-1 pathways, and testosterone optimization. These compounds work with your body's natural anabolic signaling rather than replacing it.
CJC-1295 without DAC (also called Mod GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release GH in natural pulses. The no-DAC version has a short half-life (~30 minutes), making it ideal for mimicking the body's natural pulsatile GH release pattern when timed with meals and sleep.
Subcutaneous: 100–200 mcg per injection. Timing: Best dosed before sleep or pre-workout. Combined with a GHRP (like Ipamorelin) for synergy at the same injection time. Cycle: 3–6 months on, 1–2 months off.
Cycle: 12–16 weeks on, 4–8 weeks off. Long-term use with breaks is sustainable. Onset: Sleep and recovery in 1–2 weeks; body composition at 8–12 weeks.
Well tolerated. Common: water retention at high doses, tingling (pins and needles) from GH effect, mild fatigue. Rare: insulin resistance with excessive dosing — stay within recommended range.
Ipamorelin is the cleanest and most selective growth hormone releasing peptide (GHRP) available. Unlike other GHRPs (GHRP-2, GHRP-6), it exclusively stimulates GH release without significantly raising cortisol, prolactin, or causing appetite spikes. This selective profile makes it ideal for long-term, side-effect-free GH optimization.
Subcutaneous: 200–300 mcg per injection, 2–3x daily. Best times: morning (fasted), pre-workout, and before sleep. Must be injected on an empty stomach for maximum GH pulse — food (especially carbs/fats) blunts release.
Cycle: 12–16 weeks on, 4–8 weeks off. Stack with CJC-1295. Onset: Recovery and sleep 1–2 weeks; body composition 8–12 weeks.
Very well tolerated — the cleanest GHRP. Rare: mild water retention, transient headache. Does not elevate cortisol or prolactin at therapeutic doses (key advantage over other GHRPs).
MK-677 is an oral growth hormone secretagogue and ghrelin mimetic. It increases GH and IGF-1 levels by mimicking ghrelin at the GHS-R1a receptor. Unlike injectable GH peptides, it can be taken orally and has a 24-hour half-life, making once-daily dosing sufficient. It substantially elevates IGF-1 — the primary driver of muscle protein synthesis.
Standard: 12.5–25 mg before bed (appetite surge is easier to manage during sleep). Higher doses increase side effects without proportional benefit. Run long cycles: 3–6 months for full IGF-1 elevation to manifest in muscle changes.
Cycle: 4–6 months on, 4–8 weeks off. Longer cycles than injectable due to oral convenience. Monitor for water retention and increased hunger.
Common: Increased appetite (significant), water retention, joint aches (from IGF-1 elevation), lethargy, tingling hands/feet. Monitor: Blood glucose — MK-677 can blunt insulin sensitivity. Not recommended for diabetics or pre-diabetics without physician supervision.
IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 with a modified arginine at position 3 and an added 13-amino acid extension, giving it a half-life of 20–30 hours vs. the natural IGF-1's 12–15 minutes. It directly promotes skeletal muscle hyperplasia (new muscle cells) and hypertrophy, fat mobilization, and glucose uptake.
Advanced use only: 20–50 mcg post-workout intramuscularly (to worked muscle for localized hyperplasia) or subcutaneously. Short cycles: 4 weeks on, 4 weeks off minimum. Start low and assess.
Cycle: Maximum 4 weeks then 4 weeks off. Receptor desensitization occurs with longer runs. Never exceed 4 consecutive weeks.
Common: hypoglycemia (always take with food or post-workout carbs), headache, joint swelling at high doses. Critical: Do not use fasted — hypoglycemia risk is significant. Rare: acromegaly signs with chronic overuse. Strict 4-week cycle rule is essential to prevent receptor desensitization.
Enclomiphene is the active trans-isomer of clomiphene citrate, stripped of zuclomiphene (the isomer responsible for most side effects). It acts as an estrogen receptor antagonist at the hypothalamus and pituitary, blocking negative feedback and thereby raising LH, FSH, and endogenous testosterone without suppressing sperm production.
Standard: 12.5–25 mg oral daily. Can be used continuously or cyclically. Monitor testosterone, E2, LH/FSH labs every 6–8 weeks to optimize dose. Pairs with physician guidance.
For testosterone optimization (ongoing use): Can be used continuously with regular lab monitoring every 6–8 weeks (testosterone, estradiol, LH, FSH). Most users find 12.5–25 mg daily effective long-term without needing breaks. For cyclical use: 12 weeks on, 4 weeks off minimum to allow the HPG axis to recalibrate and assess baseline. Post-cycle (PCT after TRT/steroids): 12.5–25 mg daily for 6–12 weeks until testosterone returns to natural baseline, then assess whether to continue or stop. Monitor E2: Aromatization can occur at higher testosterone levels — if estradiol rises above range, add low-dose aromatase inhibitor or reduce enclomiphene dose. Onset: LH and FSH increase within 24–48 hours; testosterone rise measurable at 2 weeks.
Common: mild estrogen-related effects if E2 rises (monitor bloodwork). Rare: visual disturbances (much less common than clomiphene). Mood changes at high doses. Monitor: Testosterone, estradiol, LH, FSH every 6–8 weeks.
Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (growth hormone-releasing hormone). It was FDA-approved for pediatric GH deficiency and is widely used off-label for adult GH restoration. Because it works through the pituitary's natural feedback loop, GH release is self-regulating — making it safer than exogenous GH.
Subcutaneous: 200–500 mcg before sleep, 5 days on / 2 days off. Benefits are gradual — expect noticeable changes at 3–6 months. Best stacked with a GHRP for amplified effect.
Cycle: 12–16 weeks on, 4–8 weeks off. Best at bedtime to align with natural GH pulse. Onset: Sleep improvement 1–2 weeks; body composition 8–12 weeks.
Well tolerated. Common: injection site redness and swelling, mild water retention, tingling/paresthesia. Rare: headache, flushing, dizziness. Fewer side effects than synthetic GH. Start at lower doses and titrate up.
Epithalon is a tetrapeptide (Ala-Glu-Asp-Gly) discovered by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. It activates telomerase, the enzyme that rebuilds telomeres — the protective caps on chromosomes that shorten with each cell division. Longer telomeres correlate directly with lifespan and disease resistance. Over 100 published studies support its anti-aging effects.
Standard protocol: 5–10 mg subcutaneous daily for 10–20 consecutive days. Frequency: 1–2 courses per year. No daily dosing needed. Some protocols use 5 mg every other day for 3 weeks. Intranasal and oral forms exist with lower bioavailability.
Cycle: 10–20 day course, 1–2 times per year. Effects persist months between courses. Pair with Pinealon for full Khavinson protocol.
Extremely well tolerated across decades of research and 100+ published studies. Rare: transient injection site reaction. No known toxicity. Among the safest anti-aging peptides available.
GLP-1 agonists, fat oxidation enhancers, and metabolic rate compounds. These work through distinct mechanisms and can be combined strategically for compounded results.
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is naturally released after eating and acts on the brain to reduce appetite, slow gastric emptying, and improve insulin sensitivity. Semaglutide's extended half-life (~7 days) allows once-weekly dosing. The most clinically validated weight loss injectable currently available.
Starting dose: 0.25 mg subcutaneous once weekly × 4 weeks. Titration: Increase by 0.25 mg every 4 weeks as tolerated. Target: 1–2.4 mg weekly. Always titrate slowly — rushing increases GI side effects dramatically.
Cycle: Long-term or indefinite for weight maintenance. Slow titration over 16 weeks. Stack with GH peptides and prioritize protein to prevent muscle loss.
Common: Nausea, vomiting, constipation, diarrhea (dose-dependent — titrate slowly). Serious (rare): Pancreatitis, gallstones. Important: Muscle loss occurs without adequate protein and exercise — this is critical to manage.
Common: nausea, vomiting, diarrhea, constipation — dose-dependent, resolve after titration. Rare: pancreatitis (discontinue with severe abdominal pain), gallbladder disease. Muscle loss without GH peptides + adequate protein. Titrate slowly over 16 weeks.
GLP3 is a dual agonist peptide that simultaneously activates both GLP-1 (glucagon-like peptide-1) and GLP-2 receptors. While GLP-1 activation drives the well-established appetite suppression and insulin sensitization effects, GLP-2 receptor activation provides an additional and distinct benefit: intestinal growth and repair. GLP-2 is naturally produced by intestinal L-cells and acts as a potent trophic factor for the gut lining — promoting epithelial cell proliferation, reducing intestinal permeability, and enhancing nutrient absorption. GLP3 therefore offers both metabolic and gastrointestinal benefits in a single compound. Available in 10mg and 20mg vials.
Research dosing protocols vary. GLP-1 effect: Dosing follows similar principles to semaglutide — start low and titrate. GLP-2 effect: GLP-2 agonists like teduglutide (FDA-approved for short bowel syndrome) are dosed at 0.05 mg/kg/day. For GLP3 research use, start at lower doses and titrate based on tolerance. Available as 10mg and 20mg vials.
Cycle: Similar protocol to GLP-1 — start conservatively and titrate. GLP-2 gut repair benefits build over 4–8 weeks.
Expected to mirror GLP-1 agonist profile: nausea, GI discomfort, appetite suppression (dose-dependent). The GLP-2 component may cause intestinal discomfort or changes in bowel habits during adaptation. Limited long-term human safety data as a dual agonist — use with appropriate caution and monitoring.
Tirzepatide is a dual GLP-1/GIP receptor agonist — the first of its kind. By activating both GLP-1 and GIP receptors simultaneously, it achieves superior weight loss and metabolic results compared to semaglutide alone. GIP activation enhances the GLP-1 effects and reduces GLP-1's nausea side effects, making tirzepatide better tolerated and more effective.
Starting dose: 2.5 mg subcutaneous once weekly × 4 weeks. Titration: Increase by 2.5 mg every 4 weeks as tolerated. Maintenance: 5–15 mg once weekly.
Cycle: Long-term for weight maintenance. Titrate 2.5 mg every 4 weeks. Max 15 mg/week. Stack with GH peptides to preserve lean mass.
Common: nausea, diarrhea, vomiting, constipation — dose-dependent and typically resolve after titration. Rare: pancreatitis risk (discontinue if severe abdominal pain). Muscle loss without GH peptides + high protein. Titrate slowly.
Retatrutide is a next-generation triple receptor agonist (GLP-1 + GIP + glucagon). By adding glucagon receptor activation to the GLP-1/GIP profile of tirzepatide, retatrutide amplifies energy expenditure and lipolysis — addressing both the "eat less" and "burn more" aspects simultaneously. Phase 3 trials show extraordinary results.
Research compound — no established clinical dosing yet. Phase 2 doses ranged from 1–12 mg once weekly. Approach with caution and start at lowest possible dose.
Cycle: Ongoing for weight maintenance. Titrate very slowly — most potent GLP class. Phase 3 trials ongoing; research use only. Estimated FDA approval 2027–2028.
Common: nausea, vomiting, decreased appetite — dose-dependent, typically improve after titration. Similar to tirzepatide profile but more pronounced at higher doses. Rare: gastrointestinal distress. Muscle loss risk without GH peptides and high protein intake. Titrate very slowly. Research use only.
AOD-9604 is a modified fragment (176-191) of human growth hormone specifically responsible for GH's lipolytic effects. It activates beta-3 adrenergic receptors in fat cells, directly stimulating lipolysis (fat breakdown) and inhibiting new fat storage, without the blood glucose or IGF-1 side effects of full-length GH.
Subcutaneous: 300–500 mcg daily, ideally in the morning fasted. Cycle: 12 weeks on, 4 weeks off. Pairs well with a GLP-1 agonist for amplified fat loss.
Cycle: 12–16 weeks on, 4–8 weeks off. Morning fasted dosing optimal. Onset: Lipolytic effects 2–3 weeks; visible fat loss at 4–6 weeks.
Very well tolerated. Rare: mild injection site reaction, transient headache. No insulin-related side effects (unlike full HGH). Among the safest fat loss compounds available.
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that impairs metabolic rate and promotes fat cell expansion. By blocking NNMT, it effectively "unlocks" the metabolic rate of fat cells — they behave more like the metabolically active fat of youth. Also increases NAD+ precursor availability.
Oral: 50–100 mg daily. Some protocols use 50 mg twice daily. Take with food. Stack with NAD+ for metabolic amplification.
Cycle: 8–12 weeks on, 4 weeks off. SubQ provides more consistent dosing than oral. Onset: Metabolic improvement in 2–4 weeks.
Generally well tolerated. Rare: mild GI discomfort, headache at higher doses. Limited long-term human safety data — cycle conservatively. SubQ provides more consistent effect than oral. Monitor metabolic markers.
L-Carnitine is a quaternary ammonium compound essential for transporting long-chain fatty acids into mitochondria for beta-oxidation. Without adequate carnitine, mobilized fat cannot be burned for fuel. Injectable L-carnitine has significantly higher bioavailability than oral forms and produces measurable athletic performance improvements.
Injectable: 500 mg–1 g subcutaneous or IM, 3–5x weekly. Best taken before fasted cardio or exercise. Oral: 2–3 g daily with carbohydrates (insulin drives carnitine uptake). ALCAR (acetyl-L-carnitine) for cognitive benefits at 500 mg–2 g daily.
Cycle: Continuous use safe. Injectable has superior bioavailability. For active fat loss phases: 2 g/day during a 12–16 week cut.
Very well tolerated. Common at high oral doses: fishy body odor, GI discomfort (nausea, cramping). Injectable form: mild injection site reaction. Rare: nausea at very high doses. Not recommended for individuals with hypothyroidism without medical supervision.
These three compounds address gut health through complementary mechanisms: structural repair, cytokine suppression, and antioxidant protection. They are most effective used together.
BPC-157 (Body Protective Compound) is the most powerful gut-healing peptide known. A 15-amino acid fragment of a protein found naturally in gastric juice, it repairs intestinal permeability, heals ulcers, reduces gut inflammation, and modulates the gut-brain axis. Crucially for gut use: BPC-157 taken orally is active directly in the GI tract — unlike most peptides, it does not need to be injected to exert its primary GI effect.
Oral (gut use): 250–500 mcg on empty stomach, 1–2x daily — swallow with water. Subcutaneous (systemic): 250–500 mcg 1–2x daily near the area of concern. Cycle: 4–8 weeks on, 2–4 weeks off.
Cycle: 4–8 weeks on, 2–4 weeks off. For IBD/ulcers: full 8-week cycles. Maintenance: 4-week cycles quarterly. Onset: GI symptoms improve in 1–3 weeks.
Extremely well tolerated. Rare: mild dizziness (nitric oxide effect), temporary nausea at high oral doses. No significant hormonal interference. One of the safest peptides available.
Glutathione is the master antioxidant tripeptide (glutamate-cysteine-glycine) essential for gut epithelial cell survival. The intestinal lining faces enormous oxidative stress from digestion, toxins, and immune activity. Glutathione neutralizes reactive oxygen species (ROS) in gut cells, supports Phase II liver detoxification of absorbed toxins, and directly regulates immune cell activity in the gut-associated lymphoid tissue (GALT). Liposomal oral delivery provides meaningful GI-level activity.
Liposomal oral: 500 mg–1 g daily for gut applications. SubQ: 200–400 mg daily. IV push: 600–1200 mg slow push 1–3x weekly for systemic loading.
Cycle: Liposomal oral: continuous. SubQ: 8–12 weeks on, 2–4 weeks off.
IV: flushing, chest tightness (rate-dependent, slow the drip). SubQ: mild injection site discomfort. Oral: GI upset at high doses. Rare: sulfur-like body odor. Very safe overall.
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminus of alpha-MSH. It acts on melanocortin receptors in intestinal epithelial cells and immune cells to directly suppress TNF-alpha, IL-1beta, and IL-6 — the cytokines driving gut inflammation in IBD, Crohn\'s, and colitis. Unlike immunosuppressants, KPV modulates rather than suppresses the immune response, making it safe for extended use. It is active when taken orally, acting directly on the gut lining without requiring systemic absorption.
Oral (gut): 250–500 mcg on empty stomach, 1–2x daily. SubQ (systemic): 500 mcg–1 mg daily. Cycle: 8 weeks on, 4 weeks off. Take oral KPV at least 30 min before eating for best absorption.
Cycle: 8 weeks on, 4 weeks off. 30 min before eating. Repeat cycles for IBD/chronic conditions. Onset: 2–4 weeks to build.
Very well tolerated. Rare: mild GI discomfort at high doses. No known immunosuppressive side effects. Safe for extended use.
Chronic inflammation underlies most age-related disease. These compounds address it through distinct molecular pathways — vascular repair, cell migration, antioxidant protection, cytokine suppression, energy restoration, and immune modulation.
BPC-157 upregulates VEGF (vascular endothelial growth factor), promotes angiogenesis in damaged tissue, and modulates nitric oxide to reduce systemic inflammation. It is simultaneously one of the most effective healing and anti-inflammatory compounds available — acting at the vascular, cellular, and neurological levels. It also protects against NSAID-induced organ damage, making it synergistic with pain management protocols.
SubQ: 250–500 mcg 1–2x daily, injected near the injury site. Oral (gut/systemic GI): 250 mcg on empty stomach. Cycle: 4–8 weeks on, 2–4 weeks off.
Cycle: 4–8 weeks acute, 2–4 weeks off. Chronic: 12-week cycles, 4-week breaks. Onset: Inflammation reduction 1–2 weeks; repair 3–6 weeks.
Cycle: 4–8 weeks on for acute injury, 2–4 weeks off. For chronic inflammatory conditions: 12-week cycles, 4-week breaks. Onset: Inflammation reduction in 1–2 weeks; tissue repair in 3–6 weeks.
Extremely well tolerated. Rare: mild dizziness, temporary nausea at high doses. No significant hormonal effects.
TB-500 is a synthetic fragment of Thymosin Beta-4 that promotes actin polymerization — enabling cell migration, the fundamental first step of tissue repair. When injected subcutaneously, TB-500 distributes systemically, reaching all sites of damage throughout the body simultaneously. It reduces scar tissue formation, increases flexibility, promotes new blood vessel growth, and has documented cardiac protective effects.
Loading: 2–2.5 mg SubQ twice weekly for 4–6 weeks. Maintenance: 2–2.5 mg once weekly or bi-weekly. Can be injected anywhere — distributes systemically.
Cycle: 6–8 week loading then 4-week break or maintenance. Ongoing: 12-week cycles, 4–6-week breaks.
Very well tolerated. Mild: fatigue and lethargy in first 1–2 days (immune activation). Rare: head rush, temporary dizziness. No steroid-like effects.
Glutathione neutralizes reactive oxygen species (ROS) — the primary drivers of inflammatory tissue damage. Every site of inflammation generates massive oxidative stress, and without adequate glutathione the inflammatory cascade becomes self-perpetuating. Glutathione also activates immune resolution pathways, helping the body transition from active inflammation to healing. Levels decline significantly with age, chronic stress, alcohol use, and chronic disease — all of which are also associated with poor healing and chronic inflammation.
SubQ: 200–400 mg daily. IV push: 600–1200 mg slow push, 1–3x weekly. Liposomal oral: 500 mg–1 g daily (far better than standard oral capsules).
Cycle: SubQ continuous or 8–12 weeks on, 2–4 weeks off. IV: weekly loading then monthly maintenance.
IV: flushing, chest tightness (rate-dependent). SubQ: mild injection site discomfort. Oral: GI upset at high doses. Very safe overall.
KPV directly suppresses TNF-alpha, IL-1beta, and IL-6 — the three master cytokines driving the most destructive forms of systemic inflammation. It does this via melanocortin receptor signaling in immune cells, without suppressing the immune response itself. This makes it uniquely safe for extended use in chronic inflammatory conditions where conventional anti-inflammatories would cause side effects with sustained use.
Oral: 250–500 mcg on empty stomach 1–2x daily. SubQ: 500 mcg–1 mg daily for systemic inflammation. Cycle: 8 weeks on, 4 weeks off.
Cycle: 8 weeks on, 4 weeks off. Repeat as needed for chronic inflammation. Effects build 2–4 weeks.
Very well tolerated. Rare: mild GI discomfort at high oral doses. No immunosuppressive effects reported.
NAD+ activates SIRT1 — a sirtuin that directly inhibits NF-kB, the master transcription factor controlling inflammatory gene expression. When NAD+ levels are high, SIRT1 is active, NF-kB is suppressed, and inflammatory gene expression is reduced throughout the body. This is why NAD+ decline with aging correlates so strongly with increased chronic inflammation (inflammaging). Restoring NAD+ is one of the most systemically impactful anti-inflammatory interventions available.
SubQ: 50–100 mg daily or alternate days. IV: 250–750 mg over 2–4 hours (most effective for rapid repletion). Oral NMN/NR: 500 mg–1 g daily (less bioavailable but convenient).
Cycle: SubQ/oral: indefinite. IV: 4–8 loading sessions then monthly. No tolerance risk.
IV: flushing, chest tightness, cramping — rate-dependent, slow the drip. SubQ: mild injection site discomfort. Oral: GI upset at high doses. Generally very safe.
SS-31 (Elamipretide) concentrates in the inner mitochondrial membrane where it protects cardiolipin — the critical phospholipid required for proper electron transport chain function. By stabilizing cardiolipin, SS-31 prevents the electron transport chain from leaking electrons as ROS (reactive oxygen species). ROS from dysfunctional mitochondria is the single largest source of chronic oxidative stress and inflammation in aging cells. SS-31 addresses inflammation at its source rather than mopping up downstream damage.
SubQ: 2–10 mg daily. For general wellness/longevity: 2–4 mg/day, 5 days on / 2 days off. Research IV protocols: 0.05 mg/kg/hr in acute cardiac settings.
Cycle: 5-on/2-off weekly. 8–12 week courses, 4 weeks off. Long-term clinical trial data supports sustained use.
Very well tolerated. Rare: mild injection site discomfort. No significant systemic side effects in clinical trials to date.
Thymosin Alpha-1 is a 28-amino acid peptide derived from the thymus gland. It restores age-related immune function decline (thymic involution), upregulates T-cell and NK cell production and activity, and reduces chronic inflammatory tone without immunosuppression. It is FDA-approved in 37 countries for hepatitis B and C, and has been used clinically for COVID-19 treatment, sepsis, and cancer immune support. It is arguably the most impactful single immune optimization compound available.
Standard: 1.6 mg SubQ twice weekly. Immune boost protocol: 1.6 mg daily for 2–4 weeks then twice weekly maintenance. Well tolerated long-term.
Cycle: 4–12 week cycles, 4–8 weeks off. Ongoing 2x/week for maintenance. Onset: Immune markers at 4–6 weeks.
Very well tolerated. Rare: mild injection site redness. No immunosuppression. Safe for long-term use.
Nootropic peptides, BDNF enhancers, and neuroprotective compounds. These work through distinct pathways — from synaptic density to neurotransmitter modulation to mitochondrial efficiency in neurons.
Semax is an ACTH analog developed in Russia, used clinically for stroke recovery, brain trauma, and cognitive decline. It dramatically upregulates BDNF (brain-derived neurotrophic factor) — the primary growth factor for neurons — while simultaneously increasing dopamine, serotonin, and acetylcholine activity. Available as a nasal spray for convenient non-injectable use.
Nasal spray: 200–600 mcg (2–6 drops of 0.1% solution) intranasally, 1–2x daily. Subcutaneous: 200–500 mcg. Cycle 4–8 weeks on, 2–4 weeks off. Morning dosing preferred — can be stimulating.
Cycle: 4–8 weeks on, 2–4 weeks off. Can be used daily within cycles. Nasal spray onset in 15–30 min. Onset: Cognitive improvement in 1–3 days; neuroplasticity effects accumulate over weeks.
Cycle: 4–8 weeks on, 2–4 weeks off. Can be used daily within cycles. Nasal spray onset in 15–30 min. Onset: Cognitive improvement in 1–3 days; neuroplasticity effects accumulate over weeks.
Well tolerated. Common at higher doses (400+ mcg): mild overstimulation, irritability, insomnia if taken too late. Rare: headache, increased anxiety in sensitive individuals. Nasal irritation with frequent spray use — alternate nostrils.
Selank is a synthetic analog of the endogenous tetrapeptide Tuftsin with added stability. It modulates GABAergic and serotonergic neurotransmission to produce anxiolytic effects without sedation or dependence. Used clinically in Russia for anxiety disorders and cognitive enhancement. It also upregulates BDNF and improves memory consolidation.
Nasal spray: 200–400 mcg 1–3x daily. Subcutaneous: 250 mcg 1–2x daily. Cycle similarly to Semax.
Cycle: No tolerance at standard doses — use as needed or 1–2x daily continuously. Best practice: 4–6 weeks on, 2 weeks off. No withdrawal risk. Onset 15–30 min intranasally.
Excellent safety profile. No sedation, no dependence, no withdrawal effects on discontinuation. Rare: mild nasal irritation with frequent spray use (alternate nostrils), slight drowsiness at very high doses. No known significant adverse effects in research to date.
Aniracetam is a fat-soluble racetam nootropic developed in the 1970s by Hoffmann-La Roche. Unlike Piracetam (water-soluble), aniracetam's fat solubility allows it to cross the blood-brain barrier more efficiently and concentrate in lipid-rich neural tissue. Its two primary mechanisms — AMPA receptor positive allosteric modulation and metabotropic glutamate receptor (mGluR) activity — produce a unique profile: cognitive enhancement combined with meaningful anxiolytic and mood-lifting effects. Widely used and well-tolerated.
Standard: 750–1500 mg, 2–3x daily. Must be taken with food containing fat — fat solubility means absorption requires dietary lipids (fish oil, avocado, or any meal works). Half-life: 1–2.5 hours, so multiple daily doses are needed. Cycle recommended: 4–6 weeks on, 2 weeks off. Some users find single 1500 mg doses at peak cognitive demand effective.
Cycle: 4–6 weeks on, 2 weeks off. Always with dietary fat. Pair with Alpha-GPC (300 mg). No significant tolerance with cycling.
Generally very well tolerated. Common: headache (choline depletion — resolve with Alpha-GPC or CDP-Choline), mild GI discomfort. Rare: irritability at high doses, mild insomnia if taken too late. Avoid high evening doses. Not recommended during pregnancy. Very low toxicity profile in all published research.
Oxiracetam is a water-soluble racetam nootropic and an analog of Piracetam, with a hydroxyl group addition that gives it notably more potent effects. Unlike aniracetam's creative/anxiolytic profile, oxiracetam leans toward stimulating logical reasoning, technical focus, mathematical thinking, and verbal precision. It has mild stimulant properties — it can enhance wakefulness and extend productive mental work sessions without the crash of caffeine.
Standard: 800–2400 mg daily, split into 2 doses (morning and early afternoon). Water-soluble — can be taken without food, though food is fine. Half-life: 6–10 hours — longer than most racetams. Avoid evening doses — the mild stimulant effect can interfere with sleep. Onset noticeable within 30–60 minutes. Cycle: 4–6 weeks on, 2 weeks off.
Cycle: 4–6 weeks on, 2 weeks off. No dosing after early afternoon. Always pair with Alpha-GPC (300 mg). Onset 1–2 hours.
Well tolerated. Common: Headache from choline depletion (always take with Alpha-GPC or CDP-Choline). Insomnia if taken in the evening. Mild overstimulation at high doses. Rare: Irritability, anxiety at very high doses (>2400 mg). Low toxicity in all research. Not recommended during pregnancy.
Dihexa is derived from Angiotensin IV and is estimated to be 10 million times more potent than BDNF at promoting synaptogenesis — the formation of new synaptic connections. It works by activating HGF/MET signaling, which drives new dendritic spine formation and synaptic density. The effects are durable — weeks to months after a short course.
Oral/Topical: 1–10 mg. Due to extreme potency, start very low (1 mg). Short cycles: 1–3 weeks on, extended off period. Effects can persist 4–6 weeks after stopping.
Cycle: 4–6 week cycles, 4–8 weeks off. Given its potency, cycle strictly and use conservatively. Limited long-term safety data.
Limited long-term human safety data. Given extreme potency (~100,000x more potent than BDNF at HGF/c-Met), dose conservatively. Rare: headache, fatigue. Theoretical concern: HGF/c-Met signaling may promote growth of pre-existing abnormal cells — avoid with active cancer history. Strict cycling is essential. Do not use daily without cycling breaks.
Pinealon is a tripeptide (Glu-Asp-Arg) developed by Khavinson that penetrates the blood-brain barrier and concentrates in the pineal and cerebral cortex cells. It regulates melatonin production, protects neurons from hypoxia-induced damage, and has demonstrated anti-aging effects on neuronal tissue in over 40 published studies.
Oral/intranasal: 0.2–1 mg daily. Subcutaneous: 0.5–1 mg daily for 10 days per course. Best combined with Epithalon for comprehensive Khavinson protocol.
Cycle: 10-day courses, 1–2 times per year. Effects persist for months between courses. Time alongside Epithalon for the full Khavinson protocol.
Very well tolerated across decades of research. Rare: transient injection site reaction. No significant adverse effects reported in any published study. Among the safest neuroprotective compounds available.
Adamax is a pre-formulated combination of Semax and Selank — the two premier Russian cognitive peptides — in a single intranasal preparation. By combining an activating, BDNF-upregulating peptide (Semax) with a calming, anxiolytic peptide (Selank), Adamax delivers enhanced focus without the anxiety edge that Semax alone can produce in some users.
2–4 sprays intranasally 1–2x daily. Morning and early afternoon preferred. Cycle 4–6 weeks on, 2 weeks off.
Cycle: 4–6 weeks on, 2–3 weeks off. More flexible than either compound alone due to balanced profile. Onset 15–30 min intranasal.
Very well tolerated — inherits Semax and Selank safety profiles. Rare: mild nasal irritation with prolonged daily spray use, occasional headache. No dependence or withdrawal reported. Some users experience mild activation at high doses — reduce dose if anxious.
Methylene Blue is one of the first synthetic drugs ever created (1876). In low doses, it acts as a mitochondrial electron carrier — donating electrons directly to Complex IV, bypassing damaged portions of the electron transport chain and dramatically improving mitochondrial efficiency, especially in neurons. It also inhibits MAO and NOS, contributing to antidepressant and neuroprotective effects.
Pharmaceutical grade only (USP). 0.5–4 mg/kg. Common doses: 10–50 mg oral daily. Warning: turns urine blue. Do not use with SSRIs or MAOIs — serotonin syndrome risk. Avoid with serotonergic supplements.
Cycle: 3x/week sustainable long-term. Some prefer 5 days on / 2 days off. Avoid doses >1 mg/kg — pro-oxidant at excess.
Common: transient blue discoloration of urine and skin (harmless, dose-dependent). Rare: headache, insomnia at high doses. Critical interaction: Do not combine with serotonergic drugs (SSRIs, MAOIs, triptans) — risk of serotonin syndrome at high doses. Avoid doses above 1 mg/kg — pro-oxidant at excess.
Modafinil is a eugeroic (wakefulness-promoting) agent FDA-approved for narcolepsy, shift work sleep disorder, and sleep apnea. It is among the most widely used and best-studied cognitive enhancers available. Unlike amphetamines, modafinil does not cause significant dopamine release burst or downstream neurotoxicity. Its primary mechanisms include inhibition of dopamine reuptake and modulation of norepinephrine, histamine, and orexin/hypocretin systems. The result is sustained wakefulness, dramatically enhanced executive function, and improved decision-making with a significantly lower side effect and addiction profile than traditional stimulants.
Modafinil: 100–200 mg oral, once in the morning. Armodafinil (R-enantiomer, Nuvigil): 75–150 mg — smoother profile, longer-lasting, preferred by many. Critical timing: Take before 9 am only — the 12–15 hour half-life means afternoon dosing will impair sleep significantly. Frequency: Maximum 3–4x per week. Daily use builds tolerance rapidly. Cycle: 3 weeks on, 1 week off. Legal status: Schedule IV controlled substance in the US — prescription required. Available OTC in some countries.
Cycle: Maximum 3–4 days per week — daily use causes rapid tolerance. Cycle: 3 weeks on, 1 week off. Do not use to chronically replace sleep.
Common: Headache, dry mouth, appetite suppression, insomnia if taken too late, mild anxiety at high doses. Less common: Nausea, jaw tension, elevated heart rate. Rare but serious: Skin rash/SJS (stop immediately), psychiatric symptoms in predisposed individuals. Significantly safer than amphetamine-class stimulants at therapeutic doses.
Phenylpiracetam was created by Russian scientists in 1983 by adding a phenyl group to Piracetam. This modification dramatically increases potency (estimated 20–60x more potent than Piracetam), blood-brain barrier penetration, and adds a pronounced stimulant dimension absent in other racetams. Sold as a prescription drug in Russia (Phenotropil/Carphedon), it is banned by the World Anti-Doping Agency (WADA) for competitive sports — one of the only nootropics to earn this distinction — due to significant physical performance enhancement including improved endurance, cold tolerance, and reaction time.
Standard: 100–200 mg oral, 1–2x daily. Critical rule: Do NOT take daily. Tolerance develops extremely rapidly — within 2–3 days of consecutive use, effects diminish significantly. Protocol: Use 2–3x per week maximum, with at least 1–2 days between doses. Best reserved for high-demand occasions: major presentations, important workouts, competitions, exams. Water-soluble — take with or without food. Half-life approximately 3–5 hours. Take in the morning or early afternoon only.
Cycle: Maximum 2–3x per week — tolerance within 2–3 consecutive days. Reserve for high-demand occasions only. Always with Alpha-GPC.
Common: Headache without choline (take Alpha-GPC), irritability if overstimulated, insomnia if taken after noon, appetite suppression. Rare: Anxiety and elevated heart rate at high doses. Do not combine with other stimulants (modafinil, caffeine at full dose, amphetamines). Primary limitation: Rapid tolerance — strict non-daily use is essential for sustained benefit. Low toxicity in all published research.
Compounds supporting the HPG axis at every level — from the hypothalamic GnRH pulse generator down to direct testicular stimulation. Full profiles for each compound.
Enclomiphene is the active trans-isomer of clomiphene citrate, stripped of zuclomiphene (responsible for most clomid side effects). It blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback on LH and FSH secretion. The result: your body naturally produces more of its own testosterone and maintains sperm production — unlike exogenous testosterone which suppresses both. This makes enclomiphene the preferred option for men who want testosterone optimization while preserving fertility.
Standard: 12.5–25 mg oral daily. Monitor testosterone, estradiol, LH, FSH labs every 6–8 weeks to optimize dose. Can be used continuously or cyclically. Physician guidance recommended for dose optimization.
Cycle: Continuous with labs every 6–8 weeks or 12 weeks on, 4 weeks off. Monitor E2.
Common: mild estrogen-related effects (monitor E2). Visual disturbances (rare — much less than clomid). Mood changes at high doses. Monitor estradiol and adjust dose if E2 rises excessively.
Gonadorelin is synthetic GnRH (gonadotropin-releasing hormone). When administered in a pulsatile fashion (every 60–120 minutes or 2–3x weekly), it stimulates the pituitary to release LH and FSH. It is commonly used alongside TRT to maintain testicular size, function, and fertility — the testes atrophy on exogenous testosterone without LH stimulation. Gonadorelin also supports natural testosterone production in men coming off TRT or anabolic steroids.
Standard: 100 mcg SubQ 2–3x weekly. For TRT fertility support: use alongside testosterone. For post-cycle: 100 mcg every other day for 4–6 weeks. Pulsatile administration (small doses frequently) is more physiological than large infrequent doses.
Cycle: Ongoing alongside TRT for testicular maintenance. Post-cycle: every other day for 4–6 weeks. Always pulsatile — never continuous.
Well tolerated. Rare: mild injection site reaction, transient hot flush, headache. Risk of receptor downregulation with continuous (non-pulsatile) administration — always use pulsatile dosing.
HCG (Human Chorionic Gonadotropin) is a glycoprotein that mimics LH (luteinizing hormone) directly at the Leydig cells in the testes. When the pituitary is suppressed (by TRT or anabolic steroids), HCG keeps the testes producing testosterone and maintaining their size and function. It is also used clinically for fertility — HCG triggers ovulation in women and stimulates sperm production in men with hypogonadotropic hypogonadism.
TRT support: 250–500 IU SubQ 2–3x weekly. Fertility protocols: 500–1000 IU 3x weekly for 3–6 months. PCT: 500–1000 IU daily for 2 weeks then taper. Physician prescription and monitoring required.
Cycle: TRT support: ongoing. PCT: 500–1000 IU daily × 2 weeks then taper. Use minimum effective dose to avoid LH receptor desensitization.
Common: testicular enlargement (intended), acne, water retention. Risk of pituitary LH receptor desensitization with very high doses. Elevated estradiol possible — monitor and manage with low-dose AI if needed. Requires prescription.
HMG (Human Menopausal Gonadotropin) is purified from the urine of postmenopausal women and contains both FSH and LH in approximately a 1:1 ratio. While HCG provides only LH-like activity (driving testosterone production), HMG adds FSH activity — essential for spermatogenesis and follicular development. HCG alone is often insufficient for sperm production in men with hypogonadotropic hypogonadism; adding HMG completes the hormonal picture. In women, HMG is used for ovarian stimulation in IVF.
Male fertility: 75 IU SubQ every other day or 3x weekly, combined with HCG. Female fertility/IVF: Per physician protocol — typically 75–150 IU daily with close monitoring. Physician prescription and ultrasound/lab monitoring required.
Cycle: Physician-supervised, typically 3–6 months for fertility goals. Always combined with HCG.
Common: injection site reactions, ovarian hyperstimulation syndrome risk in women (requires medical monitoring). In men: usually well tolerated when combined appropriately with HCG. Requires physician supervision.
Kisspeptin is the upstream master regulator of the entire reproductive axis. Kisspeptin neurons in the hypothalamus sense sex hormone levels and directly trigger GnRH (and therefore LH and FSH) release — they are the pulse generator for the entire HPG axis. Kisspeptin-10 is the active 10-amino acid fragment. Beyond fertility, kisspeptin simultaneously activates limbic arousal pathways, directly enhancing sexual desire and bonding behavior. Low kisspeptin signaling is a key mechanism in hypothalamic amenorrhea in women and low-T in men.
SubQ or intranasal: 1–10 mcg/kg. Research protocols have used single IV doses of 1 mcg/kg. For fertility applications: physician-supervised pulsatile administration protocol. For libido: 0.5–2 mg SubQ 1–2 hours before. Emerging compound — protocols still being refined.
Cycle: As-needed for libido. Fertility: physician-supervised. Conservative use given limited long-term data.
Generally well tolerated in research. Mild: LH surge symptoms (testicular ache, libido increase). Rare: flushing, nausea at high doses. Limited long-term safety data — use conservatively.
Melanocortin receptor agonists and central arousal compounds that work via the brain — not just vascular response. Each compound below has a distinct mechanism and use case.
PT-141 is an MC4R (melanocortin-4 receptor) agonist that activates arousal pathways centrally — in the hypothalamus — rather than working peripherally like PDE5 inhibitors (Viagra, Cialis). This means it increases sexual desire itself, not just vascular response. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in women, it is equally effective in men. For men with both desire and erectile dysfunction, PT-141 combined with a PDE5 inhibitor provides central arousal plus peripheral vascular coverage simultaneously.
SubQ: 0.5–2 mg injected 45–90 minutes before sexual activity. Always start at 0.5 mg to assess nausea sensitivity — titrate up in 0.5 mg increments. Intranasal: Effective nasal formulation available — similar onset window. Use maximum 1–2x per week. Allow at least 3–4 days between doses.
Cycle: As needed, maximum 1–2x per week. Allow at least 3–4 days between doses to prevent nausea sensitization. No formal cycling protocol — use on demand. Start at lowest effective dose and resist titrating higher than needed.
Common: Nausea (dose-dependent — use lowest effective dose), facial flushing, transient headache, spontaneous erections. Rare: Hypertension — do not use if cardiovascular disease present without physician clearance. Not for use with nitrates.
Melanotan II is a synthetic analog of alpha-MSH that activates MC1R (melanin production/tanning), MC3R, and MC4R (arousal and appetite). The tanning effect comes from MC1R; the libido and erectile effects from MC4R activation. Unlike MT-1 which is MC1R-selective, MT-2 provides both tanning and sexual enhancement simultaneously but with more side effects — primarily nausea. For tanning only, MT-1 is preferred. For combined tanning and libido enhancement, MT-2 is the choice.
Loading phase: Start at 100 mcg SubQ, injected in the evening. Increase by 100 mcg every few days up to 500–1000 mcg per dose once tolerance established. Maintenance: 250–500 mcg 2–3x per week once desired pigmentation achieved. Always inject in the evening — any nausea passes during sleep.
Loading phase: 2–4 weeks until target tan achieved. Maintenance: 2–3x per week ongoing. Breaks: 2–4 weeks off every 2–3 months of use. Monitor existing moles — MT-2 stimulates melanocytes and can darken nevi. Get a dermatology baseline before starting. Not recommended with numerous atypical moles or personal/family history of melanoma.
Common: Nausea (dose-dependent — evening dosing minimizes this), flushing, spontaneous erections, yawning, fatigue. Important: Monitor existing moles throughout use. Not recommended with multiple atypical moles or melanoma history.
Kisspeptin is the upstream master regulator of the entire reproductive axis. Kisspeptin neurons in the hypothalamus directly trigger GnRH (and therefore LH and FSH) release — they are the pulse generator for the entire HPG axis. Beyond fertility, kisspeptin simultaneously activates limbic arousal pathways, directly enhancing sexual desire and bonding behavior. Research shows it activates brain regions involved in romantic attraction and sexual arousal beyond simple hormone stimulation. It represents a qualitatively different type of sexual enhancement — upstream, central, and involving higher-order emotional circuitry including oxytocin co-release.
0.5–2 mg SubQ 1–2 hours before desired effect. Research doses have ranged from 1–10 mcg/kg in clinical settings. Start conservatively at 0.5 mg. For fertility applications: physician-supervised pulsatile protocols required.
Cycle: As-needed for libido and sexual enhancement — no formal cycling protocol. Fertility protocols are physician-supervised. Conservative use recommended — limited long-term safety data. Do not use continuously without breaks.
Generally well tolerated in research. Mild: LH surge-related sensations (warmth, mild ache). Rare: nausea at high doses. Limited long-term safety data — use conservatively.
Dapoxetine HCl is a short-acting selective serotonin reuptake inhibitor (SSRI) specifically engineered for on-demand treatment of premature ejaculation (PE). Unlike conventional SSRIs (fluoxetine, paroxetine) which require daily dosing and weeks to take effect, dapoxetine is designed for rapid absorption with peak plasma concentrations in 1–2 hours and a short half-life of 1.5 hours — allowing it to be used situationally, taken only when needed, with the drug cleared from the system before the next morning. Approved in over 50 countries for PE treatment. The serotonin pathway is the primary modulator of the ejaculatory reflex threshold — dapoxetine raises this threshold acutely and dose-dependently.
Standard: 30 mg oral 1–3 hours before sexual activity. If 30 mg insufficient: Titrate to 60 mg maximum. Take with a full glass of water. Do not take with alcohol — potentiates orthostatic hypotension and dizziness. Do not exceed one dose per 24 hours. Swallow whole — do not crush or split.
Cycle: On-demand use only — no daily or continuous protocol. Maximum one dose per 24 hours. Can be used regularly as needed without formal cycling, however short breaks are advisable to assess baseline. Note: If using dapoxetine regularly (>2x/week), periodic 2–4 week breaks help prevent any adaptation. Regular users should also address any psychological components of PE alongside pharmacological treatment.
Common: Nausea (most common — take with food if sensitive), headache, dizziness, diarrhea. Important: Orthostatic hypotension — stand up slowly. Do not combine with alcohol. Do not combine with other serotonergic drugs (MAOIs, other SSRIs, tramadol, triptans) — risk of serotonin syndrome. Contraindicated in patients with heart conditions, liver impairment, or those taking PDE5 inhibitors with a history of syncope. Physician consultation recommended before use.
Compounds targeting the six hallmarks of aging: telomere shortening, mitochondrial dysfunction, epigenetic drift, cellular senescence, chronic inflammation, and stem cell exhaustion. Each profile below is fully expandable.
Epithalon (Ala-Glu-Asp-Gly) is a tetrapeptide discovered by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. It activates telomerase — the enzyme that rebuilds telomeres, the protective chromosome caps that shorten with every cell division. Epithalon is the only non-pharmaceutical compound with robust published human clinical evidence for telomere extension. Beyond telomeres, it normalizes circadian rhythm, restores melatonin production, reduces tumor formation in animal models, and produced a 24% longer average lifespan in multiple animal studies. Over 100 peer-reviewed papers support its use.
Standard protocol: 5–10 mg SubQ daily for 10–20 consecutive days. Frequency: 1–2 courses per year — effects persist for months between courses. Intranasal and oral forms exist with lower bioavailability. Evening dosing preferred due to circadian effects.
Cycle: 10–20 day course, 1–2 times per year. Effects persist for months between courses — no need for daily maintenance dosing. Time alongside Pinealon for the Khavinson protocol.
Cycle: 10–20 day course, 1–2 times per year. Effects persist for months between courses — no need for daily maintenance dosing. Time alongside Pinealon for the Khavinson protocol.
Very well tolerated. No significant adverse effects across decades of use and 100+ published studies. Mild: transient injection site reaction. No known toxicity. Among the safest anti-aging compounds available.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) has over 50 years of research history. Present naturally in human plasma, it declines sharply after age 60, correlating with the loss of tissue repair capacity that defines visible aging. GHK-Cu acts as a master biological regulator — activating over 4,000 human genes involved in tissue repair, antioxidant defense, and anti-inflammatory signaling. It essentially performs an epigenetic reset toward younger gene expression patterns. It works both topically (skin, scalp) and systemically via SubQ injection.
Topical: 0.05–0.1% cream or serum applied 1–2x daily. SubQ: 500 mcg–2 mg injected 3–5x per week. Best approach: Topical daily for skin and scalp, monthly SubQ courses for systemic epigenetic effects.
Cycle: Topical: continuous daily use. SubQ: 4–8 week courses, 2–4 weeks off, repeat. Onset: Skin quality in 4–6 weeks; systemic epigenetic effects accumulate over months.
Cycle: Topical: continuous daily use. SubQ: 4–8 week courses, 2–4 weeks off, repeat. Onset: Skin quality in 4–6 weeks; systemic epigenetic effects accumulate over months.
Very well tolerated. Potential temporary skin purging (increased cell turnover) in first 2 weeks — normal and expected. Rare: mild injection site redness. Do not use high-strength retinoids on the same skin area simultaneously.
MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome — one of the very few peptides with this unique mitochondrial origin. It acts as a mitochondrial-derived peptide (MDP) that translocates to the nucleus during metabolic stress to activate AMPK and regulate metabolic homeostasis. MOTS-c levels decline with age and low levels correlate strongly with metabolic syndrome, obesity, and reduced healthspan. It extends healthspan in multiple animal models and is believed to mediate many of the systemic metabolic benefits of exercise at the cellular level.
SubQ: 5–15 mg 3–5x weekly. Loading: Some protocols use 10 mg daily for 2 weeks then 3x weekly maintenance. No established clinical human dosing — these are research-based protocols. Start conservatively.
Cycle: 8–12 weeks on, 4 weeks off. Limited long-term human data — cycle conservatively. Onset: Metabolic and energy improvement in 2–4 weeks.
Cycle: 8–12 weeks on, 4 weeks off. Limited long-term human data — cycle conservatively. Onset: Metabolic and energy improvement in 2–4 weeks.
Limited human safety data. Well tolerated in research settings. Rare: mild injection site reaction. Dose conservatively given limited long-term human data.
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell and essential for over 500 enzymatic reactions — including energy metabolism, DNA repair, and the activation of the sirtuin family of longevity proteins. NAD+ levels decline by approximately 50% between ages 40–60, and this decline is now considered a primary driver of aging: mitochondrial dysfunction, impaired DNA repair, dysregulated circadian rhythm, and chronic inflammation all trace directly to falling NAD+. Restoring NAD+ via SubQ or IV administration is among the most impactful and best-evidenced longevity interventions currently available.
SubQ: 50–100 mg daily or every other day for maintenance. IV (loading/repletion): 250–750 mg over 2–4 hours, 1–3x per month — most effective for rapid restoration. Oral NMN/NR: 500 mg–1 g daily — less bioavailable than SubQ but highly convenient for ongoing maintenance.
Cycle: SubQ/oral: continuous long-term use is sustainable and beneficial. IV: loading course then monthly maintenance. No dependence or tolerance risk.
Cycle: SubQ/oral: continuous long-term use is sustainable and beneficial. IV: loading course then monthly maintenance. No dependence or tolerance risk.
IV NAD+: Flushing, chest tightness, leg cramping — all rate-dependent; slow the drip to manage. SubQ: mild injection site discomfort. Oral: GI upset at high doses in some people. Overall very safe across all administration forms.
SS-31 (Elamipretide, MTP-131) is a cell-permeable peptide that selectively concentrates in the inner mitochondrial membrane, where it binds and stabilizes cardiolipin — a critical phospholipid required for proper electron transport chain (ETC) function. When cardiolipin becomes oxidized with aging, the ETC leaks electrons as reactive oxygen species (ROS), which drives chronic oxidative stress and inflammation. SS-31 prevents this at the source. It has demonstrated improvements in cardiac function in clinical trials and was FDA-approved in 2025 for Barth syndrome — the first approved drug targeting the mitochondrial membrane.
SubQ: 2–10 mg daily. For longevity and wellness: 2–4 mg/day, 5 days on / 2 days off. For cardiac recovery or high-performance protocols: physician-supervised higher doses.
Cycle: 8–12 week cycles, 4 weeks off for longevity use. Continuous 5-on/2-off is also well tolerated. FDA-approved safety precedent from Barth syndrome trials.
Cycle: 8–12 week cycles, 4 weeks off for longevity use. Continuous 5-on/2-off is also well tolerated. FDA-approved safety precedent from Barth syndrome trials.
Very well tolerated. Rare: mild injection site reaction. No significant systemic side effects across clinical trials. Among the best-tolerated longevity compounds available. FDA approval for Barth syndrome provides strong safety precedent.
Pinealon (Glu-Asp-Arg) is a tripeptide developed by Professor Khavinson that crosses the blood-brain barrier and selectively concentrates in the pineal gland and cerebral cortex. The pineal gland commonly calcifies with age, reducing melatonin production and disrupting circadian rhythm — a primary driver of multiple aging processes. Pinealon regulates melatonin synthesis, protects neurons from oxidative and hypoxic damage, improves cognitive function in aging models, and reduces retinal neurodegeneration. Over 40 published studies support its neuroprotective and anti-aging effects, particularly when used in combination courses with Epithalon.
SubQ: 0.5–1 mg daily for a 10-day course. Oral/nasal: 0.2–1 mg daily — lower bioavailability but convenient. Frequency: 1–2 courses per year. Best timed alongside Epithalon courses for the complete Khavinson protocol.
Cycle: 10-day courses 1–2 times per year alongside Epithalon. Effects persist for months between courses.
Cycle: 10-day courses 1–2 times per year alongside Epithalon. Effects persist for months between courses.
Very well tolerated. No significant adverse effects reported across decades of research. Mild: transient injection site reaction. Among the safest neuroprotective compounds available.
Anxiolytics, mood enhancers, and social performance compounds that reduce anxiety without sedation, blunted cognition, or dependency.
Selank is the most practical and well-tolerated anxiolytic peptide available. It modulates GABA-A receptor expression and increases serotonin turnover, producing effects similar to a low benzodiazepine dose — without sedation, cognitive impairment, tolerance, or withdrawal. For social performance it reduces threat-appraisal anxiety: the part that makes social situations feel dangerous. Alertness and verbal fluency remain fully intact or improve.
Nasal spray (preferred): 200–400 mcg, 20–45 minutes before the stressful event or 1–2x daily. SubQ: 200–400 mcg once or twice daily. Onset: 15–30 min intranasally.
Cycle: No tolerance at standard doses — can be used as needed or 1–2x daily continuously. Best practice: 4–6 weeks on, 2 weeks off. No withdrawal risk on stopping.
Excellent safety profile. No sedation, no dependence, no withdrawal. Rare: mild nasal irritation from spray use (alternate nostrils), slight drowsiness at very high doses. No known significant adverse effects in research.
Aniracetam's anxiolytic effect comes from mGluR2/3 agonism — acting on metabotropic glutamate receptors that modulate stress circuits in the amygdala and prefrontal cortex. This produces a calming effect qualitatively different from GABA compounds: rather than blunting reactivity, it improves emotional regulation, holistic thinking, and reading the room. Users consistently report reduced verbal inhibition, better social fluency, and less over-analytical anxiety. Particularly effective for anxiety that manifests as overthinking or difficulty finding words.
Standard: 750–1500 mg with a fat-containing meal, 45–60 minutes before social situations or cognitive demands. Must be taken with dietary fat — absorption without it is negligible. For daily use: 750 mg 2x daily with meals.
Cycle: 4–6 weeks on, 2 weeks off. Always with dietary fat. Pair with Alpha-GPC (300 mg per dose). No significant tolerance with proper cycling.
Generally very well tolerated. Common: Headache from choline depletion — always take with Alpha-GPC (300 mg). Mild GI discomfort without food. Rare: Irritability at high doses, mild insomnia if taken too late in the day. Very low toxicity profile in all published research.
Phenibut is a GABA-B agonist that also modulates dopamine receptors, producing pronounced anxiolysis, sociability enhancement, mild euphoria, and improved sleep quality. At therapeutic doses it dramatically reduces social anxiety, improves verbal fluency, and creates natural ease in social situations. It is among the most effective social performance compounds available — but carries serious tolerance and withdrawal risk that strictly limits use frequency. Reserve for genuinely high-value occasions.
HCl form: 500–1500 mg, taken 4–6 hours before desired effect (slow onset). FAA (free amino acid) form: 250–750 mg, 1–2 hour onset — faster and more bioavailable. Take on empty stomach. Start at lowest dose.
Cycle: Maximum 1–2x per week, minimum 3 days between doses. Never daily — rapid tolerance and severe withdrawal (anxiety rebound, insomnia, dysphoria) develops within 2–3 consecutive daily uses. Take 2–4 week breaks after any period of regular use.
Common: Sedation at high doses, cognitive slowing, next-day grogginess at high doses. Serious: Tolerance develops within 2–3 consecutive daily doses. Withdrawal includes severe anxiety rebound, insomnia, dysphoria, and in extreme cases (daily high-dose use) seizures. Never combine with alcohol or benzodiazepines — dangerous CNS depression.
L-Theanine is an amino acid found naturally in tea leaves that crosses the blood-brain barrier and directly increases alpha brain wave activity — the neurological state associated with relaxed alertness, creativity, and flow. It reduces glutamatergic excitatory activity and modestly increases GABA and serotonin. Unlike most anxiolytics it produces zero sedation, zero cognitive impairment, and zero tolerance with daily use. The caffeine + L-Theanine combination is one of the most well-validated cognitive performance protocols in existence.
For anxiety: 100–400 mg daily. With caffeine: 200 mg theanine per 100 mg caffeine (2:1 ratio). Safe with or without food, any time of day.
Cycle: Continuous indefinite daily use is safe and beneficial — no tolerance, no withdrawal. One of the only anxiolytics appropriate for permanent daily use.
Extremely safe. No significant adverse effects at any therapeutic dose. Very rare: headache at very high doses (>600 mg). No toxicity, no dependence, no withdrawal.
KPV acts on melanocortin receptors to suppress TNF-alpha, IL-1beta, and IL-6 — the cytokines that directly impair serotonin and dopamine synthesis. Chronic low-grade inflammation is a major but under-recognized driver of anxiety. KPV's anti-inflammatory action on the gut-brain axis contributes to measurable anxiolytic and mood-stabilizing effects, particularly for anxiety with concurrent gut issues, brain fog, or fatigue alongside anxiety.
Oral (gut + systemic): 250–500 mcg on empty stomach, 1–2x daily. Take 30 min before eating for best gut absorption. SubQ: 500 mcg–1 mg daily for systemic anti-inflammatory effects.
Cycle: 8 weeks on, 4 weeks off. Anti-inflammatory anxiolytic effects build over 2–4 weeks of consistent use. Repeat cycles as clinically indicated.
Very well tolerated. Rare: mild GI discomfort at high oral doses. No immunosuppressive effects — immune modulation only. Safe for extended cycles.
DSIP directly reduces corticotropin (ACTH) and cortisol release — the primary stress hormones driving anxiety and hypervigilance. High chronic cortisol is one of the most common physiological causes of anxiety and creates a vicious cycle: anxiety elevates cortisol, which worsens anxiety. DSIP breaks this cycle at the hormonal root. Particularly targeted for morning anxiety, racing thoughts at night, and stress-induced sleep disruption. Available as nasal spray.
Cycle: 2–4 weeks on, 2 weeks off. 3–5x per week rather than daily to prevent receptor adaptation. Onset: Sleep quality improvement in 3–7 days; cortisol normalization measurable over 2–3 weeks.
Very well tolerated at therapeutic doses. Rare: mild drowsiness, transient headache. No next-day sedation. No withdrawal on discontinuation. Do not use before driving until individual response is known.
At lower doses (200–300 mcg), Semax produces calming and mood-elevating effects via serotonin receptor sensitization and dopamine system modulation — before the activating BDNF surge that dominates at higher doses (400+ mcg). This low-dose window is particularly useful for mood support, mild social anxiety, and motivation enhancement. At higher doses the activating effects predominate — useful for focus but can increase anxiety in sensitive individuals.
Cycle: 4–6 weeks on, 2 weeks off. At 200–300 mcg the calming effect predominates. Stack with Selank for Adamax-like profile. Onset: 15–30 min intranasally.
Well tolerated at low doses (200–300 mcg). Common at higher doses (400+ mcg): mild overstimulation, irritability, insomnia if taken too late. Rare: headache, increased anxiety in sensitive individuals. Nasal irritation with frequent spray use — alternate nostrils.
Goal-organized stacking protocols. Each stack includes core compounds, supportive additions, and optimal timing. Compounds are color-coded: gold = core, green = supportive, italic = optional enhancement.
Reconstituting peptides involves aseptically mixing lyophilized powder with a diluent. Follow these steps exactly for safe, effective preparation.
Gather your lyophilized peptide vial, bacteriostatic water, and a 1 mL syringe with a 27–30 gauge needle. Lay everything on a clean, disinfected surface. Wash your hands thoroughly.
Wipe the rubber stopper on both the peptide vial and the bacteriostatic water vial with a fresh alcohol swab. Allow to air dry for 10–15 seconds before inserting any needle.
Draw the correct volume of bacteriostatic water into your syringe. The amount depends on the peptide concentration you want. Common ratio: 1 mL BAC water per 10 mg of peptide powder = 1000 mcg per 0.1 mL (100 units on an insulin syringe). Adjust based on your dosing needs.
Insert the needle into the peptide vial and angle it so the water runs down the inner side wall of the vial — not directly onto the powder. This prevents foaming and mechanical degradation of the peptide. Inject slowly, not in a forceful stream.
Gently swirl the vial in a circular motion. Never shake. Vigorous agitation creates foam and can break peptide bonds, degrading potency. The powder should dissolve into a clear solution. If it doesn't fully dissolve, let it sit for 15–30 minutes at room temperature.
Allow the solution to sit undisturbed for 15–30 minutes to ensure complete dissolution. The solution should be clear — a slight yellow tint is normal in some peptides but cloudiness, particles, or significant color change may indicate a problem.
Write on the vial with a permanent marker: the peptide name and the date of reconstitution. Reconstituted peptides stored in bacteriostatic water are stable refrigerated (2–8°C) for 4–6 weeks. Keep away from light. Never freeze a reconstituted peptide.
Nasal spray peptides are reconstituted the same way but typically with sterile saline (0.9% NaCl) rather than bacteriostatic water — the benzyl alcohol preservative in BAC water can irritate nasal mucosa at high concentrations.
Example: You have 5 mg (5000 mcg) of BPC-157. You add 1 mL (100 units on a U-100 insulin syringe) of BAC water.
Tip: Adding more BAC water = lower concentration per unit = larger volume per dose. Adding less = higher concentration = smaller volume. Adjust to what's comfortable for injecting.
Select your peptide, enter your vial and water amounts, and see exactly how many units to draw.
New to peptides? Start here. This guide walks through the essentials — what peptides are, how to approach them safely, and the best starting compounds by goal.
Peptides are short chains of amino acids — the same building blocks as proteins — that act as signaling molecules in the body. They instruct cells to produce more of something (collagen, growth hormone, melanin) or to modulate a process (inflammation, fat burning, healing). Unlike hormones or steroids, most peptides work by amplifying your body's own processes rather than replacing them. This is why they generally have excellent safety profiles when used correctly.